Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 18;328(15):1559-1561.
doi: 10.1001/jama.2022.17811.

Odds of Hospitalization for COVID-19 After 3 vs 2 Doses of mRNA COVID-19 Vaccine by Time Since Booster Dose

Jessica P Ridgway  1 , Samuel Tideman  2 , Thomas French  2 , Bill Wright  2 , Guilford Parsons  2 , George Diaz  3 , Ari Robicsek  2
Affiliations

Odds of Hospitalization for COVID-19 After 3 vs 2 Doses of mRNA COVID-19 Vaccine by Time Since Booster Dose

Jessica P Ridgway et al. JAMA. .
No abstract available

Plain language summary

This study assesses the association between COVID-19 mRNA booster immunization compared with vaccination with the primary mRNA vaccination series alone and odds of hospitalization for COVID-19.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Ridgway reported receiving personal fees from Gilead Sciences. Dr Diaz reported receiving grants from Gilead, Roche, Regeneron, Edesa Biotech Inc, Boehringer Ingelheim, NeuroBo Pharmaceuticals Inc, and the National Institutes of Health and serving as a scientific board member for Safeology. No other disclosures were reported.

Figures

Figure.
Figure.. Odds of Hospitalization for COVID-19 After 3 vs 2 Doses of mRNA COVID-19 Vaccine by Time Since Booster Dose
The shaded areas indicate the 95% CIs. The 30-day rolling average is depicted.
See this image and copyright information in PMC

References

    1. Accorsi EK, Britton A, Shang N, et al. . Effectiveness of homologous and heterologous Covid-19 boosters against Omicron. N Engl J Med. 2022;386(25):2433-2435. doi:10.1056/NEJMc2203165 - DOI - PMC - PubMed
    1. Andrews N, Stowe J, Kirsebom F, et al. . Effectiveness of COVID-19 booster vaccines against COVID-19–related symptoms, hospitalization and death in England. Nat Med. 2022;28(4):831-837. doi:10.1038/s41591-022-01699-1 - DOI - PMC - PubMed
    1. Wright BJ, Tideman S, Diaz GA, French T, Parsons GT, Robicsek A. Comparative vaccine effectiveness against severe COVID-19 over time in US hospital administrative data: a case-control study. Lancet Respir Med. 2022;10(6):557-565. doi:10.1016/S2213-2600(22)00042-X - DOI - PMC - PubMed
    1. Tartof SY, Slezak JM, Puzniak L, et al. . Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the Omicron and Delta variants in a large health system in the USA: a test-negative case-control study. Lancet Respir Med. 2022;10(7):689-699. doi:10.1016/S2213-2600(22)00101-1 - DOI - PMC - PubMed
    1. Butt AA, Talisa VB, Shaikh OS, Omer SB, Mayr FB. Relative vaccine effectiveness of a SARS-CoV-2 mRNA vaccine booster dose against the Omicron variant. Clin Infect Dis. 2022;ciac328. doi:10.1093/cid/ciac328 - DOI - PMC - PubMed

MeSH terms